United-Guardian Inc is a Delaware corporation. The company through its Guardian Laboratories Division manufactures and markets cosmetic ingredients, personal care products, pharmaceuticals, medical and health care products, and specialty industrial products. It also conducts research and development, related to the development of new and cosmetic and personal care products. The Company's products are separated into four distinct product categories: personal care products (including cosmetic ingredients), pharmaceuticals, medical products, and industrial products. The Company's personal care products include; LUBRAJELTM is a line of water-based moisturizing and lubricating gel formulations that are used as ingredients in personal care consisting of cosmetic & skin care; LUBRAJEL PF is different from the other products in the LUBRAJEL line in that it is a completely preservative-free form of LUBRAJE; LUBRAJEL NATURAL is a natural form of LUBRAJEL for cosmetic use based on natural polysaccharides, which contribute moisturization, emulsion stabilization, and emolliency to personal care creams and lotions; its other personal care products include; LUBRASIL, LUBRAJEL II XD, KLENSOFT, UNITWIX, ORCHID COMPLEX, LUBRASLIDE, and HYDRAJEL PL. the Company's medical products includes; LUBRAJEL RR and RC are both gels used as lubricants for urinary catheters; LUBRAJEL LC was developed for a specific customer who required a product suitable for oral use, to be used in a line of mouth moisturizers that it markets; LUBRAJEL MG is the original form of LUBRAJEL, developed as a medical lubricant; and LUBRAJEL FLUID is a very low viscosity form of LUBRAJEL that was developed to provide superior lubrication in water-soluble products. The Company's Pharmaceuticals products include; RENACIDIN a prescription drug product that is used to prevent and to dissolve calcifications in urethral catheters and the urinary bladder and marked as a ready-to-use sterile solution; and CLORPACTIN WCS-90 an antimicrobial product used in urology to treat infections in the urinary bladder. It is also used in surgery for treating a wide range of localized infections in the peritoneum as well as the eye, ear, nose and throat, and sinuses. The Company's industrial product includes; DESELEX Liquid a sequestering and chelating agent that is used as a replacement for phosphates in the manufacture of detergents and also use in personal care products as a chelating agent in shampoos and body washes; and POLYCOMPLEX M and Q an complexing agents capable of producing clear solutions of specific water-insoluble materials. The products are sold directly to those marketing partners, which in turn resell those products to their customers for use in the manufacture or compounding of the customers' personal care and cosmetic products. The Company's non-pharmaceutical medical products and the specialty industrial products are sold directly by the Company to the end users or to contract manufacturers utilized by the end users. The Company's pharmaceutical products are marketed by direct advertising, mailings, and trade exhibitions, and are sold to end users mainly through drug wholesalers, which purchase the Company's products outright for resale to their customers. The Company also sells a small quantity of pharmaceutical products directly to hospitals and pharmacies. The Company's products are sold under trademarks or trade names owned by the Company. The marks for the important products, LUBRAJEL and RENACIDIN, as well as some other Company trademarks, are registered as trademarks with the United States Patent and Trademark Office as well as with the appropriate regulatory agencies in some foreign countries. The Company faces competition from other domestic and foreign companies that are engaged in the same or similar areas of research. Any medical device products developed by the Company will be subject to FDA regulation.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.